Goldman Sachs analyst Salveen Richter downgraded bluebird bio (NASDAQ: BLUE) from Buy to Neutral with a price target of $23.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

bluebird bio (BLUE) PT Lowered to $19 at Morgan StanleyAugust 11, 2021 8:26 AM bluebird bio (BLUE) PT Lowered to $26 at RBC CapitalAugust 10, 2021 6:13 AM Wells Fargo Downgrades bluebird bio (BLUE) to Equal WeightAugust 10, 2021 6:08 AM William Blair Reinstates bluebird bio (BLUE) at Market PerformAugust 10, 2021 4:29 AM bluebird bio (BLUE) PT Lowered to $21 at BMO Capital, Following Earnings, Business UpdateAugust 9, 2021 3:50 PM bluebird bio (BLUE) PT Lowered to $29 at Mizuho Securities, Following Earnings, Business UpdateAugust 9, 2021 3:32 PM bluebird bio (BLUE) PT Lowered to $37 at JPMorgan, Following Earnings, Business UpdateAugust 9, 2021 2:33 PM bluebird bio (BLUE) PT Lowered to $18 at StifelAugust 9, 2021 1:56 PM SVB Leerink Downgrades bluebird bio (BLUE) to Market Perform, Following Earnings, Business UpdateAugust 9, 2021 12:45 PM bluebird bio (BLUE) Misses Q2 EPS by 39cAugust 9, 2021 7:12 AM Form 10-Q bluebird bio, Inc. For: Jun 30August 9, 2021 7:05 AM Form 8-K bluebird bio, Inc. For: Aug 09August 9, 2021 7:03 AM bluebird bio Reports Second Quarter Financial Results and Provides Operational UpdateAugust 9, 2021 7:00 AM